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INTRODUCTION
The patients infected with hepatitis C virus (HCV) have
different clinical outcomes, ranging from acute resolving
hepatitis to chronic liver disease including liver cirrhosis or
hepatocellular carcinoma. Approximately 25-30% of indi-
viduals with chronic HCV infections have persistently normal
alanine aminotransferase (ALT) level (1, 2) and these indi-
viduals are usually referred to as “healthy carrier” of HCV
(3). However, several studies have demonstrated that the
histological features of most healthy carriers showed chronic
liver damage of a variable degree, ranging from mild hep-
atitis to liver cirrhosis (4-8), and thus the existence of the
true “healthy carrier” of HCV is still debatable. 
Because the relationship of serum ALT level to liver dam-
age or viral replication in chronic HCV carriers remain
unclear, liver biopsy is essential to evaluate the degree of
liver damage in these subjects. However, it is practically
difficult to perform liver biopsy in all asymptomatic healthy
carriers with normal ALT level (9, 10), and therefore, non-
invasive approach is required to make an accurate diagnosis
on such cases.
Recently, many studies have attempted to investigate the
relationship between the characteristics of HCV at molecu-
lar level and histological liver damage or the clinical outcome
of the patients with chronic hepatitis C, especially those
receiving interferon therapy (11, 12). However, studies on
the correlations between HCV RNA titers or HCV geno-
type, and the severity of liver damage have shown conflict-
ing results (13-17). In addition, whether HCV RNA titer is
a better predictor of underlying liver injury than serum
ALT is not known.
For many years, chronic hepatitis has been classified into
chronic persistent hepatitis (CPH), chronic active hepatitis
(CAH), and chronic lobular hepatitis (CLH). However, this
conventional classification has not fully provided the infor-
mation to predict the natural course of chronic hepatitis. For
liver biopsy specimens of chronic hepatitis, Knodell et al.
proposed a numerical scoring system, the Histology Activi-
ty Index (HAI), which was graded into four categories: peri-
portal necrosis, intralobular necrosis, portal inflammation,
and fibrosis (12). Recently, this index is more commonly used
for the evaluation of clinical course or therapeutic response
of the patients with chronic hepatitis. 
The aim of the present study was to determine whether
the degree of histological damage correlates with virological
features of HCV and serum ALT level in patients with chron-
ic hepatitis C.
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The Relationship of Histologic Activity to Serum ALT, HCV genotype
and HCV RNA titers in Chronic Hepatitis C
It is unclear whether serum ALT levels or virological characteristics of hepatitis
C virus(HCV) including HCV genotypes and HCV RNA titers, can reflect the
degree of histological injury in chronic hepatitis C. The aim of this study was to
investigate the relationships between the levels of histological damage and
serum ALT levels, HCV genotypes or circulating HCV RNA titers in chronic hep-
atitis C. A total of 56 patients underwent liver biopsy and the histological activity
index (HAI) was evaluated by Knodell’ s scoring system. HCV genotype by RT-
nested PCR and HCV RNA quantitation by competitive RT-PCR were per-
formed. Thirty-four patients were infected with HCV genotype 1b, 20 patients
with genotype 2a, and 2 patients with undetermined type. Serum ALT levels
were not positively correlated with total HAI score or HCV RNA titers, but
showed a linear correlation with scores of piecemeal necrosis (r=0.32, p<0.05)
and portal inflammation (r=0.27, p<0.05). HCV genotype had no significant cor-
relation with RNA titers, HAI score or with serum ALT levels. Also, no statistical
relationship was seen between HCV RNA titer and HAI score. These results
suggest that liver histology is essential to evaluate  the severity of chronic hep-
atitis C precisely.
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MATERIALS AND METHODS
Patients (Table 1)
Fifty-six consecutive subjects with hepatitis C who had
undergone liver biposy were enrolled from Kangnam St.
Mary’ s Hospital. They consisted of 36 men and 20 women
with ages ranging from 18 to 73 yr (mean=46 yr). The diag-
nosis of chronic hepatitis C was made on the basis of elevat-
ed serum ALT level for more than 6 months, positivity for
anti-HCV antibody by the second generation enzyme immu-
noassays (EIA), the confirmation of HCV RNA by reverse
transcription-polymerase chain reaction (RT-PCR), and by
histology of liver biopsy specimens. Patients with positive
serum HBsAg or autoantibodies (antinuclear antibody, anti-
smooth muscle antibody, and antimitochondrial antibody),
or history of alcohol abuse or taking a herbal medicine or
plant alkaloids or clinical (ascites and variceal bleeding) hema-
tologic (leukopenia and thrombocytopenia) or biochemical
(hypoalbuminemia, hyperbilirubinemia, and prolonged
prothrombin time) evidence of portal hypertension or hep-
atic failure by liver cirrhosis were excluded from the study. 
Biochemical and Serological tests
Anti-HCV assay was determined by second-generation
EIA (Abbott Laboratories, Chicago, Ill, U.S.A.). HBsAg was
tested with a radioimmunoassay (Abbott Laboratories, Chica-
go, Ill, U.S.A.). Serum ALT level was determined at the time
of liver biopsy. Anti-nuclear, anti-smooth muscle, and anti-
mitochondrial antibodies were determined by immunofluo-
rescence and titers>1/40 were considered positive.
Histological Assessment 
All subjects gave their informed consents to liver biopsy.
Formalin-fixed, paraffin-embedded specimens were routine-
ly stained with hematoxylin-eosin and histological exami-
nation was carried out by one pathologist according to the
conventional criteria. Histological scores were determined
according to the Knodell’ s HAI scoring system which is
most widely used. The HAI score (0-22 points) consists of
four major elements: 1) periportal +/- bridging necrosis (0-
10) 2) intralobular degeneration and focal necrosis (0-4); 3)
portal inflammation (0-4), and fibrosis (0-4). 
Detection and genotyping of HCV RNA
HCV RNA was detected from sera of the patients by RT-
PCR using primers from the 5′ non-coding region, as de-
scribed previously (18).
HCV genotypes were determined with type-specific pri-
mers on second round PCR following first amplification of
the NS5 gene with universal primer pair as described else-
where (19, 20). The nomenclature of HCV genotype fol-
lowed to scheme proposed by Simmonds et al. (21). The
oligonucleotide primer sequences used are were as follows:
universal primer, sense-5′ -TGG GGA TCC CGT ATG
ATA CCC GCT GCT; universal primer, antisense-5′ -GGC
GGA ATT CCT GGT CAT AGC CTC CGT GAA-3′ ; geno-
type 1a, sense-5′ -CGA CAT CCGT ACG GAG GAGG-3′ ;
genotype 1a, antisense-5′ -CAG GCT GCC CGG GCC
TTG AT-3′ ; genotype 1b, sense-5′ -TGA CAT CCG TGT
TGA GGA GT-3′ ; genotype 1b, antisense-5′ -CGG GCC
GCA GAG GCC TTC AA-3′ ; genotype 2a, sense-5′ -TAT
GTT CAA CAG CAA GGG CCA GA-3′ ; genotype 2a,
antisense-5′ -CCT GGT CAT AGC CTC CGT GAA-3.
Quantification of serum HCV RNA
Serum HCV RNA level was quantified by a competitive
RT-PCR using a synthetic mutant HCV RNA as a compet-
itive template as describes previously (18). Briefly, the syn-
thesis of cDNA following HCV RNA extraction was done
by reverse transcription. An equal amount of sample RNA
was put into a set of microtubes that already had 10-fold
serially diluted mutant RNA plus annealing mixture con-
taining primer KL70. After cDNA synthesis, second round
PCRs were performed. The sequences of primers used were:
HCV QC1, sense-5′ -CCA CCA TAG ATC ACT CCC CTGT
-3′ and HCVL70, antisense-5′ -TTG AGG TTT AGG ATT
CGT GCT CAT-3′ for the first PCR; HCVQC2, sense-5′ -
CTG TGA GGA ACT ACT GTC TTCA-3′ and HCVQC3,
antisense-5′ -ACT CGC AAG CAC CCT ATC AGGC-3′
for second PCR. A 10  L of second PCR products was ana-
lyzed by electrophoresis on 2.5% agarose gel containing
No. of Patients 56
Sex (M/F) 36/20
Mean age (yr) (range) 46 (18-73)
ALT (IU/L) (range)* 129.4±82.2 (11-438)
Albumin (g/dL)* 3.8±0.5
Total bilirubin (mg/dL)* 1.6±0.7
WBC (/ L)* 5,200±1030
Platelet (/ L)* 185,000±24,500
Prothrombin index (%) 93.5±7
Anti-HCV positivity (%) 100
HCV RNA positivity (%) 100
HCV RNA titer (range)
� 5.9 (4.6-7.6)
HCV genotype (number of subjects) 
HCV 1b 34
HCV 2a 20
Undetermined 2
Histologic Activity Index
Mean grading 1.5±0.9
Mean staging 2.1±1.2 
Table 1. Clinical characteristics of patients with chronic hep-
atitis subjected in this study
*Mean±SD, 
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ethidium bromide and visualized by ultraviolet transillumi-
nator. The titer of circulating HCV RNA was defined by
log10 (copy number of HCV RNA per milliliter of serum). 
Statistical Analysis 
The correlations among histologic scores, the ALT level,
and the HCV RNA titers were analyzed by the Spearman
rank-order correlation coefficient. A p value less than 0.05
was considered statistically significant. To determine whether
there was any difference in the histological features between
the two genotypic groups, the mean ranks by genotypic
group of the histological parameters were compared by
Mann-Whitney test.
RESULTS
Correlation between HAI score and serum ALT level
Demographic and virological features of the patients are
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Fig. 2. The relationship between serum ALT levels and individual component of HAI score : periportal inflammation (A), portal inflamma-
tion (B), intralobular degeneration (C) and fibrosis (D). Good correlations of periportal inflammation (r=0.3215, p<0.05) and portal inflam-
mation (r=0.2672, p<0.05) to serum ALT levels are seen. However, there is no significant correlation between serum ALT levels and
intralobular degeneration or fibrosis.
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Fig. 1. The relationship between serum ALT levels and total HAI
score in patients with chronic hepatitis C. The correlation is not
significant (r=0.2537, p>0.05).
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shown in Table 1. As the serum ALT increased, the total HAI
score also increased, but significant correlation between the
two groups was not observed (rs=0.2537, p=0.057) (Fig. 1).
In relationship between separate component of HAI and
ALT level (Fig. 2), the degree of piecemeal necrosis (rs=
0.3215, p=0.037) and portal inflammation (rs=0.2672, p=
0.041) significantly correlated with ALT level. However, no
significant correlation between the degree of intralobular
degeneration (rs=0.0812, p=0.115) or fibrosis (rs=0.2595,
p=0.082) and ALT level was seen.
Correlation between HAI score and circulating HCV
RNA titer
Circulating HCV RNA levels through competitive RT-
PCR assay were determined by comparing the signal inten-
sities of two bands on agarose gel electrophoresis as shown
in Fig. 3. Amplified PCR products derived from the target
HCV RNA in sera and the mutant HCV RNA as internal
template were 268 base pairs (bp) and 188 bp, respectively. 
Although the patients with worse histology had a trend
toward higher HCV RNA titers, there was no significant
correlation between circulating HCV RNA titers and the
degree of liver injury (rs=0.2495, p=0.058). (Table 2, Fig.
4). None of the individual components of the HAI score in
relation to circulating HCV RNA levels showed statistical-
ly significant value.
Correlation between HAI score and Genotype of HCV 
For the determination of HCV genotype, the HCV NS5
region was amplified by second round PCR with type-spe-
cific primers. Of the 56 patients, 34 (60.7%) were infected
with genotype 1b, 20 (35.7%) with genotype 2a, and 2
(3.6%) with undetermined genotype. Histological differ-
ences between genotype 1b and genotype 2a were compared
by the Mann-Whitney test and no significant differences
were seen (Table 3).
DISCUSSION
Chronic HCV infection affects approximately 3% of the
population worldwide and HCV accounts for approximately
20% of cases of acute hepatitis and 70% of cases of chronic
hepatitis (1, 22). The clinical outcome of HCV infections is
believed to depend mostly on the balance between the rate
of replication of the infecting virus and the capacity of the
immune system to mount rapid, multi-specific and efficient
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Fig. 4. The relationship between HCV RNA titer and total HAI
score. No significant correlation is found between two parame-
ters.
188 bp 
(internal 
template)
268 bp 
(sample RNA)
Fig. 3. Competitive RT-PCR assay for measuring HCV RNA
titers. Determination of HCV RNA levels in sera. Amplification
products were visualized by ethidium bromide staining after gel
electrophoresis. 268 and 315 bp DNA bands represent amplifi-
cation products derived from native HCV RNA and internal con-
trol RNA, respectively. Position(�) of equal intensities of both
bands is the HCV RNA titer deduced from sera (4×104
copies/mL).
4×105 4×104 4×103 4×102 4×101 4×100 (copies/mL)
1-5 (mild) 27 4.6-7.6 (mean:5.7)
6-10 (moderate) 19 4.6-7.6 (mean:6.1)
11-22 (severe) 10 5.3-6.6 (mean:6.0)
Biopsies (n) 
Table 2. Range of HCV RNA titers according to histologic
activity index (HAI) by Knodell scoring system
Range of HCV RNA titers
(log copies/mL)
HAI
(degree of hepatitis)
Genotype 1b 0 (0,5) 27.94 1 (0,3) 26.93 1 (1,4) 28.07 1 (0,4) 26.85
Genotype 2a 0 (0,5) 25.32 1 (0,3) 27.13 1 (1,3) 25.08 3 (0,4) 27.26
p value 0.523 0.956 0.409 0.92
Table 3. Histological scores as measured by Knodell scoring
systems comparing genotype 1b with  genotype 2a. For each
category, results are listed as median score (range of score)
and finally mean rank for each genotype group
Periportal
inflammation
Portal
inflammation
Intralobular 
degeneration FibrosisHistology and ALT and Virological Characteristics of HCV 589
virus-specific responses to inhibit infection before the virus
can devise strategies to evade immune surveillance (23).
However, little is known about the precise role played by
host or viral factors in the pathogenesis of liver damage due
to HCV.
In general, chronic hepatitis C patients with elevated ALT
levels and high HCV RNA titers in the sera are considered
to have active HCV replication in the liver and to be at risk
for continued liver injury in a clinical basis. Also, the serum
ALT level is recognized as a marker reflecting the degree of
the histological damage and has served as a parameter for
starting therapy or judging response to antiviral treatment
in chronic hepatitis C. However, a number of recent studies
showed ambivalent results in the relationships among the
degree of histological damage, serum ALT level, HCV RNA
titers and HCV genotype in chronic hepatitis C (11, 13, 24-
30).
The aim of this study was to address whether there was a
correlation between the degree of histological damage and
serum ALT level or virological characteristics including HCV
RNA titers or HCV genotype in chronic hepatitis C. 
The results of this study revealed no significant correla-
tion between serum ALT level and total HAI. But some
individual components of the HAI score such as piecemeal
necrosis and portal inflammation correlated with degree of
ALT elevation. Our observations are in agreement with pre-
vious reports that showed significant hepatic histological
abnormalities in patients with normal or near-normal serum
ALT levels (24) and poor correlation between higher serum
ALT levels and histological abnormalities (28, 30). These
results suggest that serum ALT levels do not accurately pre-
dict the presence of liver damage, although it seems to cor-
relate with the severity of architectural changes. Thus, it is
essential to assess the histological activity of liver damage in
order to reassure the subjects with minimal disease and to
identify patients with advanced chronic liver disease (4, 9). 
Recently many studies regarding HCV RNA titer and its
correlation to HAI score have shown conflicting results. In
our study, there was no significant correlation between cir-
culating HCV RNA titers and the degree of liver injury.
Interestingly, 38.5% of 26 patients with high viremic levels
had a mild hepatitis (HAI ≤5), while 16.7% of 30 patients
with low viremic levels showed severe hepatitis (HAI ≥11)
on liver biopsy. In addition, none of the individual compo-
nents of the HAI score in relation to circulating HCV RNA
levels should a statistically significant result. Previous data
showed discrepant results between HCV RNA titers and
HAI, while some studies revealed no correlation (15, 25, 28).
Still others showed a significant relationship (11, 13, 29).
Many factors may account for these discrepancies. Firstly,
the test used to quantitate HCV RNA was different accord-
ing to the studies. Gretch et al. indicated the limitations of
the bDNA assay for quantitation of HCV RNA, especially
when viremia is very low or very high (13). Secondly, because
serum HCV load fluctuates and that is not a stable parame-
ter, it can not reflect the degree of liver damage in a given
subject (31). Thirdly, HCV replicates in extra-hepatic sites
as well as within the liver (32). Thus a high amount of cir-
culating HCV do not always imply a more active state of
viral replication in the liver, nor a more severe degree of
liver disease (33). Lastly, the discrepancy may result from
the time interval between tests of ALT and HCV RNA and
performing liver biopsy. Furthermore, the determination of
enzyme level on a single serum sample might not be related
to the ALT profile over time (34). However, in this study
both ALT test and HCV RNA titer were drawn on the same
day with the liver biopsy. 
The clinical outcome of HCV infection can be influenced
by the HCV genotype. Previous data revealed that genotype
1 was found in a higher percentage of chronic active hepati-
tis and cirrhosis with respect to other genotypes (35), and
that the rate of response to interferon was higher in patients
infected with genotypes 2 and 3 (36). The absence of ALT
elevation despite evidence of chronic hepatitis might be
related to infection with a specific HCV genotype and/or to
a lower degree of viral replication (37). Genotype 2 was
mainly associated with persistently normal or near-normal
ALT levels, whereas genotype 1b was prevalent among sub-
jects with elevated ALT (37). However, in the present study,
no statistical relationship was found between liver damage
and HCV genotype. This observation is in consistent with
previous report demonstrating that HCV genotype have lit-
tle influence on the progression of chronic liver disease (38). 
In conclusion, our study shows that viral load or HCV
genotype does not accurately predict the degree of liver injury
in chronic HCV carriers, although serum ALT levels weakly
correlate with portal inflammation and periportal necrosis.
Thus, the histological evaluation would be the gold standard
to accurately assess the degree of liver damage and to decide
therapeutic plan in patients chronically infected with HCV. 
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